Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ejiao Composite Syrup is a Traditional Chinese Medicine (TCM) formulation developed by Dongzhimen Hospital, affiliated with the Beijing University of Chinese Medicine. It is specifically designed to treat diminished ovarian reserve (DOR) and related female reproductive health issues. The syrup is a multi-ingredient preparation featuring Ejiao (Colla Corii Asini) as its primary component, combined with other herbs such as Rehmannia glutinosa and Angelica sinensis. Its pharmacological action is centered on the regulation of the hypothalamic-pituitary-ovarian (HPO) axis, where it helps balance serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2). Additionally, it has been shown to improve ovarian blood flow and inhibit the apoptosis of ovarian granulosa cells, thereby enhancing follicular development and overall fertility potential in women with declining ovarian function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ejiao Composite Syrup.